Study wrapper · #933
Retatrutide in type 2 diabetes mellitus and obesity: an overview.
Panou T, Gouveri E, Popovic DS, et al. Expert review of clinical pharmacology. 2026.
DOI: 10.1080/17512433.2026.2642415PubMed: 41785010
Editor's note
This narrative overview is centered on retatrutide and consolidates trial findings across diabetes, obesity, and fatty liver outcomes. It reports strong associations with glycemic, weight, and hepatic fat improvements while flagging dose-dependent gastrointestinal effects. As a narrative review it summarizes rather than adds primary evidence.
Plain-language abstract
An overview summarizing evidence that retatrutide is associated with lower HbA1c, substantial weight loss, reduced blood pressure, and large reductions in liver fat, with dose-related gastrointestinal side effects.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular preventionn=——2026